Clinical Trials

136 results for Prostate Cancer


Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Other: Laboratory Biomarker Analysis, Radiation: Radiation Therapy
  • Study ID: NCT01833208
View Trial

18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.

  • Condition: Bone Metastases, Prostate Cancer
  • Intervention: Other: scintigraphy 99mTc-MDP-SPECT/CT., Other: 18F-NaF-PET/MR
  • Study ID: NCT02969564
View Trial

A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
  • Intervention: Drug: sodium selenite, Radiation: radiation therapy, Other: laboratory biomarker analysis, Other: pharmacological study, Other: questionnaire administration
  • Study ID: NCT02184533
View Trial

A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

  • Condition: Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, Recurrent Prostate Cancer
  • Intervention: Drug: onapristone, Drug: abiraterone
  • Study ID: NCT02049190
View Trial

A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Cabazitaxel, Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Prednisone
  • Study ID: NCT02522715
View Trial

A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cance

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Biological: Glycosylated Recombinant Human Interleukin-7, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01881867
View Trial

A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
  • Intervention: Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Drug: Niclosamide, Other: Pharmacological Study
  • Study ID: NCT02532114
View Trial

A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel
  • Study ID: NCT02985021
View Trial

STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherap

  • Condition: Prostate Cancer
  • Intervention: Drug: celecoxib, Drug: docetaxel, Drug: prednisolone, Drug: ADT, Drug: zoledronic acid, Drug: abiraterone, Procedure: orchiectomy, Radiation: Radiotherapy to the prostate, Drug: enzalutamide
  • Study ID: NCT00268476
View Trial

A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02598895
View Trial

A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: EC1169, Other: EC0652
  • Study ID: NCT02202447
View Trial

A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])

  • Condition: Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Sirolimus
  • Study ID: NCT02565901
View Trial

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

  • Condition: Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
  • Intervention: Radiation: Stereotactic Radiosurgery
  • Study ID: NCT02206334
View Trial

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Biological: Pembrolizumab, Biological: pTVG-HP Plasmid DNA Vaccine
  • Study ID: NCT02499835
View Trial

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

  • Condition: Castration Resistant Metastatic Prostate Cancer
  • Intervention: Drug: Testosterone cypionate, Drug: Enzalutamide, Drug: Testosterone Enanthate
  • Study ID: NCT02286921
View Trial

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castrate-resistant Prostate Cancer, mCRPC
  • Intervention: Drug: Sipuleucel-T, Radiation: Stereotactic Ablative Body Radiation
  • Study ID: NCT01818986
View Trial

A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Apalutamide, Drug: Abiraterone acetate, Drug: Docetaxel, Drug: Prednisone
  • Study ID: NCT02913196
View Trial

A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)

  • Condition: Prostate Cancer
  • Intervention: Drug: Abiraterone acetate, Drug: Prednisone, Drug: ARN509, Drug: Ipilimumab, Drug: Cabazitaxel, Drug: Carboplatin
  • Study ID: NCT02703623
View Trial

A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: GT0918
  • Study ID: NCT02826772
View Trial

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry

  • Condition: Prostatic Neoplasms
  • Intervention: Other: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
  • Study ID: NCT02364531
View Trial

A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT02236637
View Trial

Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide

  • Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Selinexor
  • Study ID: NCT02215161
View Trial

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Metastatic Castrate-Resistant Prostate Cancer
  • Intervention: Drug: GS-5829, Drug: Enzalutamide
  • Study ID: NCT02607228
View Trial

TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)

  • Condition: Prostate Cancer
  • Study ID: NCT02512185
View Trial

Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Sipuleucel-T, Procedure: Lymph Node Biopsy
  • Study ID: NCT02036918
View Trial

A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Radium-223, Biological: Sipuleucel-T
  • Study ID: NCT02463799
View Trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab 200 mg, Drug: Olaparib 400 mg, Drug: Docetaxel 75 mg/m^2, Drug: Prednisone 5 mg, Drug: Enzalutamide 160 mg, Other: Dexamethasone 8 mg
  • Study ID: NCT02861573
View Trial

PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

  • Condition: Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Abiraterone acetate, Drug: Sipuleucel-T
  • Study ID: NCT02353715
View Trial

A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Taxotere, Drug: Jevtana
  • Study ID: NCT02044354
View Trial

Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

  • Condition: Prostatic Neoplasms
  • Intervention: Other: 18F-Sodium Fluoride (NaF)
  • Study ID: NCT02677376
View Trial

A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: ZEN003694
  • Study ID: NCT02705469
View Trial

A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: ZEN003694, Drug: Enzalutamide
  • Study ID: NCT02711956
View Trial

A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Niraparib
  • Study ID: NCT02854436
View Trial

Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance

  • Condition: Prostate Cancer
  • Intervention: Procedure: Image-Guided Biopsies
  • Study ID: NCT02432001
View Trial

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: Abiraterone acetate, Drug: Enzalutamide
  • Study ID: NCT02125357
View Trial

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Rucaparib, Drug: Abiraterone acetate or Enzalutamide or Docetaxel
  • Study ID: NCT02975934
View Trial

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Rucaparib
  • Study ID: NCT02952534
View Trial

A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Dietary Supplement: Ascorbic Acid, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Placebo, Other: Quality-of-Life Assessment
  • Study ID: NCT02516670
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or M

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Ipatasertib, Drug: Abiraterone, Drug: Placebo
  • Study ID: NCT03072238
View Trial

A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

  • Condition: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
  • Intervention: Drug: enzalutamide, Drug: mifepristone, Other: laboratory biomarker analysis, Other: pharmacological study
  • Study ID: NCT02012296
View Trial

Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT03176381
View Trial

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer Metastatic
  • Intervention: Behavioral: High intensity aerobic and resistance training, Behavioral: Psychosocial support
  • Study ID: NCT02730338
View Trial

A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status

  • Condition: Prostate Cancer
  • Intervention: Drug: radium-223
  • Study ID: NCT03002220
View Trial

Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Intervention: Drug: Xofigo (Radium-223 dichloride, BAY88-8223
  • Study ID: NCT02899104
View Trial

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Isovue-M 200
  • Study ID: NCT03071328
View Trial

Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223

  • Condition: Prostate Cancer Metastatic, Bone Metastases
  • Intervention: Drug: Radium-223 dichloride
  • Study ID: NCT03223597
View Trial

Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223

  • Condition: Prostate Cancer Metastatic, Bone Metastases
  • Intervention: Diagnostic Test: Blood tests
  • Study ID: NCT03223727
View Trial

A Randomized, Open Label, Phase IIB Trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated With Docetaxel

  • Condition: Prostate Cancer Metastatic, Metastasis
  • Intervention: Drug: Cabazitaxel, Drug: Abiraterone, Drug: Enzalutamide
  • Study ID: NCT03295565
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial